Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 6/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.34 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9174030 | 0.92 | MAPT (0.42) | AKR1C3MAPTPOLBSTSCA1 | |
| SCHEMBL6864127 | 0.86 | AKR1C3 (0.33) | AKR1C3 | |
| SCHEMBL7868038 | 0.85 | AKR1C3 (0.34) | AKR1C3ESR1ESR2CYP3A4 | |
| SCHEMBL5891654 | 0.85 | AKR1C3 (0.34) | AKR1C3ESR1ESR2CYP3A4 | |
| SCHEMBL8653835 | 0.84 | MAPT (0.46) | MAPTPOLBSTSCYP2C9ABCC4 | |
| SCHEMBL5891671 | 0.84 | AKR1C3 (0.33) | AKR1C3 | |
| SCHEMBL9178008 | 0.82 | POLB (0.48) | MAPTPOLBCYP2C9CYP19A1LMNA | |
| SCHEMBL8653911 | 0.82 | MAPT (0.48) | AKR1C3MAPTPOLBSTSCYP2C9 | |
| SCHEMBL8654083 | 0.82 | MAPT (0.42) | MAPTPOLBSTSCA1CA2 | |
| SCHEMBL8768216 | 0.81 | AKR1C3 (0.32) | AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148213-B2 | Antigestagenically active steroids with a fluorinated 17α-alkyl chain | SCHERING AG (DE) | 2006-12-12 | — | — | US | disclosed |
| US-20050080060-A1 | Antigestagenically active steroids with a fluorinated 17alpha-alkyl chain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-14 | — | — | US | disclosed |
| US-6806263-B2 | NEW 17 ALPHA -FLUOROALKYL STEROIDS OF GENERAL FORMULA I AS ANTIESTROGENS | SCHERING AG (DE) | 2004-10-19 | — | — | US | disclosed |
| US-20030134834-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | SCHERING AG (DE) | 2003-07-17 | — | — | US | disclosed |
| US-6503895-B2 | Antigestagenically active steroids with a fluorinated 17α-alkyl chain | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-01-07 | — | — | US | disclosed |
| US-20020045774-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-18 | — | — | US | disclosed |
| EP-0970103-B1 | ANTIGESTAGENIC STEROIDS WITH A FLUORINATED 17ALPHA-ALKYL CHAIN | SCHERING AG (DE) | 2002-04-17 | — | — | EP | disclosed |
| US-6316432-B1 | ANTIESTROGENS AND ANTIFERTILITY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-13 | — | — | US | disclosed |
| US-5405979-A | Stereoselectively reducing phenyl-substituted estradiene with electropositive metal in electron-solvating solvent, cleaving ketone protective group with acid | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-04-11 | — | — | US | disclosed |
| EP-0532562-B1 | PROCESS FOR PRODUCING 10$g(b)-H-STEROIDS | SCHERING AG (DE) | 1994-11-23 | — | — | EP | disclosed |
| WO-1991018918-A1 | PROCESS FOR PRODUCING 10β-H-STEROIDS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134834-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | HSD17B11, HSD3B1, CYP17A1 | AKR1C3 90/4885MAPT 4877/4885POLB 283/4885 |
| US-20020045774-A1 | Antigestagenically active steroids with a fluorinated 17-alpha-alkyl chain | HSD17B11, NR5A1, HSD3B1 | AKR1C3 86/4885MAPT 4871/4885POLB 478/4885 |
| US-20050080060-A1 | Antigestagenically active steroids with a fluorinated 17alpha-alkyl chain | NR5A1, HSD17B11, CYP21A2 | AKR1C3 45/4885MAPT 4863/4885POLB 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.